Profile 

Founded in 1988, the Department of Pharmacy at the Second Affiliated Hospital of Soochow University has been recognized as a key specialty department in Suzhou. The department has a total of 113 pharmacy professionals, including 28 senior pharmacists (Associate Chief Pharmacists and above), 67 pharmacists-in-charge, and 18 pharmacists. The department of pharmacy comprises three sub-specialties: clinical pharmacy, the pharmacy dispensing/pharmacy intravenous admixture services (PIVAS), and the drug clinical trial institution. The clinical pharmacy division is designated as both a National Clinical Pharmacist Training Base and a National Rational Drug Use Demonstration Base. The pharmacy dispensing department/PIVAS has achieved the automation, informatization, and intelligent management of medication dispensing and the entire process of drug management. The Phase I clinical trial unit conducts early-stage clinical research, including single-dose, multiple-dose, food effect, and drug interaction studies, as well as bioequivalence studies, generic drug evaluations, pharmacokinetic studies in special populations, and human mass balance and biotransformation studies for ¹⁴C-labeled innovative drugs. The precision pharmacy research center focuses on therapeutic drug monitoring and model-guided clinical research, providing a strong platform for personalized drug therapy and clinical drug research.

Clinical Pharmacy Services

The department comprises 13 full-time, standardized-trained pharmacists serving 15 specialties, including 5 with teaching certifications. This team provides services in medication consultation,review, prescription evaluation, patient education, and pharmaceutical care for complex and critical cases. Specialized pharmacy clinics are also operated to perform medication reconciliation for chronic patients on multiple medications. Real-time audits of hospital-wide prescriptions and orders are conducted through pre-review software to ensure accuracy and appropriateness. Over the past three years, clinical pharmacists have participated in 388 multidisciplinary consultations, conducted 1,320 independent consultations, reviewed an average of 68,370 prescriptions annually, and evaluated an average of 5,353 medical records per year.

Pharmacy Dispensing

The pharmacy dispensing department/PIVAS is equipped with fully automated pill dispensing machines, a single-dose packaging system, intelligent drug storage units, an automatic infusion sorting machine, and a PIVAS intelligent labeling machine. The department has implemented a comprehensive set of systems, including a pharmacy information system, rational drug use monitoring system, narcotic drug management system, peritoneal dialysis solution distribution management system, prescription collection system, and an inpatient pharmacy management system. These systems have enabled the automation, informatization, and intelligence of drug dispensing, drug management, and rational drug use oversight. The outpatient department processes an average of 1,931,004 prescriptions annually, with a total drug consumption of 827,584,158 yuan. It handles an average of 1,220,829 intravenous preparations and 3,486,708 inpatient orders per year, maintaining a 100% review rate for both outpatient prescriptions and inpatient orders.

Drug Clinical Trial

The standardized drug clinical trial center has registered 18 pharmaceutical specialties and 22 equipment specialties, conducting over 600 clinical trials to date, including more than 150 international multicenter and imported registration trials, over 100 clinical trials for medical devices and in vitro diagnostic reagents, and over 150 registered products. The Phase I clinical trial unit has 62 research-oriented beds, including 33 general beds, 9 intensive care beds, 2 emergency beds, 12 isotope beds, and 6 for glucose clamp studies. It has successfully conducted over 160 trials, encompassing FIH, BE studies, and consistency evaluations. The center enables advanced research on human substance balance and biotransformation of ¹⁴C-labeled innovative drugs. 

Data Updated until Nov 2024